Page 20 - Relapse News Today

Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients.

DEAR ABBY: I was married for 20 years. We met when I was 13. Our relationship continued through high school and college. We later married and had three children. I

DISCOMS trial has provided data to guide decisions, now it's all about individualized discussions

Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.

Specialists engage in a conversation regarding the treatment duration and the effectiveness of the current two-year approach.

The 3-year relapse and mortality rates for thrombotic thrombocytopenic purpura (TTP) were 23.6% and 26.3%, predicated on platelet count.

results of this MD Anderson study were recently published in Cancers and indicate the relevance of enumeration of Circulating Tumor Cells (CTCs) with the ...

Blissful Thinking: A Memoir of Overcoming the Wellness Revolution charts one woman's difficult search for nirvana.

Panelists discuss the impact of pandemic-influenced process changes and shifting standards of care for the treatment of schizophrenia.

A recent study suggests that treatment with modern antidepressants may help prevent patients with bipolar disorder from relapsing into a depressive episode.